Combined therapy for small cell undifferentiated carcinoma of the lung

I. Mandelbaum, S. D. Williams, N. B. Hornback, B. T. Joe, Lawrence Einhorn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Fifty-eight patients with small cell lung cancer were treated from September, 1974, to March, 1976, with combined chemotherapy and radiotherapy. Surgical resection of the lung lesion was performed in three patients, and a number of surgical diagnostic methods were carried out in the remaining patients with unresectable or disseminated lesions. Nineteen patients were from the Veterans Administration Hospital and 39 from Indiana University Medical Center. The median Karnofsky performance status was 60. Thirty-nine patients had extensive disease, and 19 had disease limited to the chest and supraclavicular area. All patients received chest radiotherapy and prophylactic whole brain radiation. Adriamycin, cyclophosphamide, and vincristine were given on day 1 and continued every 3 weeks. There were 27 (48 percent) partial remissions of a median duration of 26 weeks. There were 25 patients (43 percent) with complete remission. The median survival for the entire group was 51 weeks. Six of 58 patients (10 percent) are alive and disease free from 24 to 38 months after treatment. Six of 19 patients with limited disease (32 percent) are presently alive and disease free. This includes one patient in whom surgical resection was performed. Combined therapy influences favorably the prognosis of small cell cancer of the lung, especially in those patients with limited disease and favorable performance status.

Original languageEnglish (US)
Pages (from-to)292-296
Number of pages5
JournalJournal of Thoracic and Cardiovascular Surgery
Volume76
Issue number3
StatePublished - 1978
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Carcinoma
Lung
Therapeutics
Small Cell Lung Carcinoma
Radiotherapy
Thorax
Veterans Hospitals
Karnofsky Performance Status
United States Department of Veterans Affairs
Vincristine
Doxorubicin
Cyclophosphamide
Radiation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Mandelbaum, I., Williams, S. D., Hornback, N. B., Joe, B. T., & Einhorn, L. (1978). Combined therapy for small cell undifferentiated carcinoma of the lung. Journal of Thoracic and Cardiovascular Surgery, 76(3), 292-296.

Combined therapy for small cell undifferentiated carcinoma of the lung. / Mandelbaum, I.; Williams, S. D.; Hornback, N. B.; Joe, B. T.; Einhorn, Lawrence.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 76, No. 3, 1978, p. 292-296.

Research output: Contribution to journalArticle

Mandelbaum, I, Williams, SD, Hornback, NB, Joe, BT & Einhorn, L 1978, 'Combined therapy for small cell undifferentiated carcinoma of the lung', Journal of Thoracic and Cardiovascular Surgery, vol. 76, no. 3, pp. 292-296.
Mandelbaum, I. ; Williams, S. D. ; Hornback, N. B. ; Joe, B. T. ; Einhorn, Lawrence. / Combined therapy for small cell undifferentiated carcinoma of the lung. In: Journal of Thoracic and Cardiovascular Surgery. 1978 ; Vol. 76, No. 3. pp. 292-296.
@article{59b54b7b42cd46fe8ea656e2cb393832,
title = "Combined therapy for small cell undifferentiated carcinoma of the lung",
abstract = "Fifty-eight patients with small cell lung cancer were treated from September, 1974, to March, 1976, with combined chemotherapy and radiotherapy. Surgical resection of the lung lesion was performed in three patients, and a number of surgical diagnostic methods were carried out in the remaining patients with unresectable or disseminated lesions. Nineteen patients were from the Veterans Administration Hospital and 39 from Indiana University Medical Center. The median Karnofsky performance status was 60. Thirty-nine patients had extensive disease, and 19 had disease limited to the chest and supraclavicular area. All patients received chest radiotherapy and prophylactic whole brain radiation. Adriamycin, cyclophosphamide, and vincristine were given on day 1 and continued every 3 weeks. There were 27 (48 percent) partial remissions of a median duration of 26 weeks. There were 25 patients (43 percent) with complete remission. The median survival for the entire group was 51 weeks. Six of 58 patients (10 percent) are alive and disease free from 24 to 38 months after treatment. Six of 19 patients with limited disease (32 percent) are presently alive and disease free. This includes one patient in whom surgical resection was performed. Combined therapy influences favorably the prognosis of small cell cancer of the lung, especially in those patients with limited disease and favorable performance status.",
author = "I. Mandelbaum and Williams, {S. D.} and Hornback, {N. B.} and Joe, {B. T.} and Lawrence Einhorn",
year = "1978",
language = "English (US)",
volume = "76",
pages = "292--296",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Combined therapy for small cell undifferentiated carcinoma of the lung

AU - Mandelbaum, I.

AU - Williams, S. D.

AU - Hornback, N. B.

AU - Joe, B. T.

AU - Einhorn, Lawrence

PY - 1978

Y1 - 1978

N2 - Fifty-eight patients with small cell lung cancer were treated from September, 1974, to March, 1976, with combined chemotherapy and radiotherapy. Surgical resection of the lung lesion was performed in three patients, and a number of surgical diagnostic methods were carried out in the remaining patients with unresectable or disseminated lesions. Nineteen patients were from the Veterans Administration Hospital and 39 from Indiana University Medical Center. The median Karnofsky performance status was 60. Thirty-nine patients had extensive disease, and 19 had disease limited to the chest and supraclavicular area. All patients received chest radiotherapy and prophylactic whole brain radiation. Adriamycin, cyclophosphamide, and vincristine were given on day 1 and continued every 3 weeks. There were 27 (48 percent) partial remissions of a median duration of 26 weeks. There were 25 patients (43 percent) with complete remission. The median survival for the entire group was 51 weeks. Six of 58 patients (10 percent) are alive and disease free from 24 to 38 months after treatment. Six of 19 patients with limited disease (32 percent) are presently alive and disease free. This includes one patient in whom surgical resection was performed. Combined therapy influences favorably the prognosis of small cell cancer of the lung, especially in those patients with limited disease and favorable performance status.

AB - Fifty-eight patients with small cell lung cancer were treated from September, 1974, to March, 1976, with combined chemotherapy and radiotherapy. Surgical resection of the lung lesion was performed in three patients, and a number of surgical diagnostic methods were carried out in the remaining patients with unresectable or disseminated lesions. Nineteen patients were from the Veterans Administration Hospital and 39 from Indiana University Medical Center. The median Karnofsky performance status was 60. Thirty-nine patients had extensive disease, and 19 had disease limited to the chest and supraclavicular area. All patients received chest radiotherapy and prophylactic whole brain radiation. Adriamycin, cyclophosphamide, and vincristine were given on day 1 and continued every 3 weeks. There were 27 (48 percent) partial remissions of a median duration of 26 weeks. There were 25 patients (43 percent) with complete remission. The median survival for the entire group was 51 weeks. Six of 58 patients (10 percent) are alive and disease free from 24 to 38 months after treatment. Six of 19 patients with limited disease (32 percent) are presently alive and disease free. This includes one patient in whom surgical resection was performed. Combined therapy influences favorably the prognosis of small cell cancer of the lung, especially in those patients with limited disease and favorable performance status.

UR - http://www.scopus.com/inward/record.url?scp=0018120906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018120906&partnerID=8YFLogxK

M3 - Article

C2 - 210332

AN - SCOPUS:0018120906

VL - 76

SP - 292

EP - 296

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 3

ER -